Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH.

Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15.

PMID:
24735962
2.

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.

Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.

Br J Haematol. 2013 Oct;163(2):182-93. doi: 10.1111/bjh.12503. Epub 2013 Aug 8.

PMID:
23927424
3.

Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia.

Lanemo Myhrinder A, Hellqvist E, Bergh AC, Jansson M, Nilsson K, Hultman P, Jonasson J, Buhl AM, Bredo Pedersen L, Jurlander J, Klein E, Weit N, Herling M, Rosenquist R, Rosén A.

Leuk Lymphoma. 2013 Aug;54(8):1769-79. doi: 10.3109/10428194.2013.764418. Epub 2013 Feb 25.

PMID:
23297799
4.

Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.

Vojdeman FJ, Jurlander J, van't Veer M, Itälä-Remes M, Kimby E, Tjønnfjord GE, Walewski J, Kozák T, Polliack A, Montagna M, Regazzi M, Kirkby N, van Oers M, Geisler CH.

Leuk Lymphoma. 2013 Apr;54(4):790-3. doi: 10.3109/10428194.2012.720373. Epub 2013 Jan 4.

PMID:
23025267
5.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, Davis Z, van Gastel-Mol EJ, Tresoldi C, Chu CC, Cahill N, Giudicelli V, Tichy B, Pedersen LB, Foroni L, Bonello L, Janus A, Smedby K, Anagnostopoulos A, Merle-Beral H, Laoutaris N, Juliusson G, di Celle PF, Pospisilova S, Jurlander J, Geisler C, Tsaftaris A, Lefranc MP, Langerak AW, Oscier DG, Chiorazzi N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.

Blood. 2012 May 10;119(19):4467-75. doi: 10.1182/blood-2011-11-393694. Epub 2012 Mar 13.

6.

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity.

Kostareli E, Gounari M, Janus A, Murray F, Brochet X, Giudicelli V, Pospisilova S, Oscier D, Foroni L, di Celle PF, Tichy B, Pedersen LB, Jurlander J, Ponzoni M, Kouvatsi A, Anagnostopoulos A, Thompson K, Darzentas N, Lefranc MP, Belessi C, Rosenquist R, Davi F, Ghia P, Stamatopoulos K.

Leukemia. 2012 May;26(5):1127-31. doi: 10.1038/leu.2011.311. Epub 2011 Nov 4. No abstract available.

PMID:
22051533
7.

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R.

Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5.

8.

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.

Kaderi MA, Kanduri M, Buhl AM, Sevov M, Cahill N, Gunnarsson R, Jansson M, Smedby KE, Hjalgrim H, Jurlander J, Juliusson G, Mansouri L, Rosenquist R.

Haematologica. 2011 Aug;96(8):1153-60. doi: 10.3324/haematol.2010.039396. Epub 2011 Apr 20.

9.

Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily.

Tholstrup D, Brown Pde N, Jurlander J, Bekker Jeppesen P, Groenvold M.

Leuk Lymphoma. 2011 Mar;52(3):400-8. doi: 10.3109/10428194.2010.541310. Epub 2011 Jan 21.

PMID:
21250826
10.

TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.

Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G, Jurlander J, Juliusson G, Rosenquist R.

Leuk Res. 2011 Feb;35(2):272-4. doi: 10.1016/j.leukres.2010.08.023. Epub 2010 Sep 25.

PMID:
20870288
11.

Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

Marincevic M, Mansouri M, Kanduri M, Isaksson A, Göransson H, Smedby KE, Jurlander J, Juliusson G, Davi F, Stamatopoulos K, Rosenquist R.

Haematologica. 2010 Dec;95(12):2072-9. doi: 10.3324/haematol.2010.028639. Epub 2010 Aug 26.

12.

Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk.

Crowther-Swanepoel D, Mansouri M, Enjuanes A, Vega A, Smedby KE, Ruiz-Ponte C, Jurlander J, Juliusson G, Montserrat E, Catovsky D, Campo E, Carracedo A, Rosenquist R, Houlston RS.

Br J Haematol. 2010 Aug;150(4):473-9. doi: 10.1111/j.1365-2141.2010.08270.x. Epub 2010 Jun 10.

PMID:
20553269
13.

High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Marincevic M, Cahill N, Gunnarsson R, Isaksson A, Mansouri M, Göransson H, Rasmussen M, Jansson M, Ryan F, Karlsson K, Adami HO, Davi F, Jurlander J, Juliusson G, Stamatopoulos K, Rosenquist R.

Haematologica. 2010 Sep;95(9):1519-25. doi: 10.3324/haematol.2009.021014. Epub 2010 Apr 26.

14.

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.

Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJ, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS.

Nat Genet. 2010 Feb;42(2):132-6. doi: 10.1038/ng.510. Epub 2010 Jan 10.

15.

A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence.

Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N, Moreno C, Anagnostopoulos A, Jurlander J, Tsaftaris A, Chiorazzi N, Belessi C, Ghia P, Rosenquist R, Davi F, Stamatopoulos K.

Leukemia. 2010 Jan;24(1):125-32. doi: 10.1038/leu.2009.186. Epub 2009 Sep 17.

PMID:
19759557
16.

Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.

Gunnarsson R, Isaksson A, Mansouri M, Göransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R.

Leukemia. 2010 Jan;24(1):211-5. doi: 10.1038/leu.2009.187. Epub 2009 Sep 10. No abstract available.

PMID:
19741724
17.

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.

Kaderi MA, Mansouri M, Zainuddin N, Cahill N, Gunnarsson R, Jansson M, Kimby E, Aleskog A, Lundin J, Glimelius B, Melbye M, Juliusson G, Jurlander J, Rosenquist R.

Leuk Res. 2010 Mar;34(3):335-9. doi: 10.1016/j.leukres.2009.06.006. Epub 2009 Jul 1.

PMID:
19573916
18.

Propionic acid secreted from propionibacteria induces NKG2D ligand expression on human-activated T lymphocytes and cancer cells.

Andresen L, Hansen KA, Jensen H, Pedersen SF, Stougaard P, Hansen HR, Jurlander J, Skov S.

J Immunol. 2009 Jul 15;183(2):897-906. doi: 10.4049/jimmunol.0803014. Epub 2009 Jun 24.

19.

Limited impact of the thymus on immunological recovery during and after chemotherapy in patients with diffuse large B-cell lymphoma.

Vedel SJ, Tholstrup D, Kolte L, Gaardbo J, Ryder LP, Ersbøll A, Albrecht-Beste E, Jurlander J, Nielsen JO, Nielsen SD.

Scand J Immunol. 2009 Jun;69(6):547-54. doi: 10.1111/j.1365-3083.2009.02252.x.

20.

Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia.

Geisler C, Jurlander J, Bullinger L, Sander S, Brown P, Benner A, Philip P, Döhner H, Stilgenbauer S; Danish CLL-2 study group.

Eur J Haematol. 2009 Aug;83(2):156-8. doi: 10.1111/j.1600-0609.2009.01258.x. Epub 2009 Mar 19. No abstract available.

PMID:
19302558

Supplemental Content

Loading ...
Support Center